poisar

Stocks · News reference

XORTX Therapeutics Terminates And Postpones Investor Relations And Marketing Agreement With IR Agency

Aug 28, 2026, 11:19 AMBenzinga Newsdesk

XORTX Therapeutics Inc. ("XORTX" or the "Company") NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

XRTX
Source
benzinga
Observed
Aug 28, 2026, 11:19 AM
Checked
Aug 28, 2026, 11:19 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 28, 2026, 11:00 AMNa

    XORTX Announces Termination and Postponement of Investor Relations Program

    XORTX Therapeutics has terminated its US$2.5 million investor relations and marketing agreement with IR Agency LLC effective August 7, 2026, with all funds returned to the company. The decision was made to postpone the IR program during the company's voluntary delisting from the TSX Venture Exchange, expected to take effect September 1, 2026. The company aims to reduce regulatory complexity and focus resources on clinical development. Additionally, XORTX disclosed previously omitted finder's fees of US$240,000 related to its April 2026 acquisition of Vectus Biosystems' Renal Anti-Fibrotic Therapeutic Program.

    Read original at globenewswire-inc
    XRTX